Roivant partners with Pfizer and launches new company for experimental bowel disease treatment | The Financial Express

Roivant partners with Pfizer and launches new company for experimental bowel disease treatment

Both therapies under the deal are antibodies that work against the TL1A protein, the excess presence of which has been linked to inflammatory diseases.

Roivant partners with Pfizer and launches new company for experimental bowel disease treatment
Last year, Pfizer launched its patient charter that defined how they interact and assist patients across the country. (File)

Roivant Sciences, a biotech firm, on Thursday launched a company with Pfizer Inc. focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion-dollar market.

According to a report by news agency Reuters, the drug, RVT-3101, was originally developed by Pfizer, which will hold a 25% stake in the new business, with Roivant holding the majority interest.

The deal hands over the development of the drug to the new company, along with commercial rights to the treatment in the United States and Japan for no upfront payment. Reportedly, Pfizer will hold commercial rights outside of the two countries.

SVB Securities analyst David Risinger said as quoted by Reuters the deal shows how Pfizer is prioritizing research spending for its oral ulcerative colitis drug, etrasimod, which holds a near-term blockbuster opportunity.

Etrasimod, which Pfizer had acquired as part of its $6.7 billion deal for Arena Pharmaceuticals last year, succeeded in a second late-stage study earlier this year.

Both partners will pay a mid-single digit royalty to each other in respective territories, said Roivant Chief Executive Matt Gline. He added that data from the induction portion of the ongoing study will be shared in a matter of “weeks to a month”.

The new unit also has the option to develop and co-commercialize a second antibody therapy for inflammatory and fibrotic diseases with the U.S. drugmaker.

Both therapies under the deal are antibodies that work against the TL1A protein, the excess presence of which has been linked to inflammatory diseases.

RVT-3101 could represent a nearly $15 billion commercial opportunity in the United States for Roivant as a treatment for both ulcerative colitis and Crohn’s disease, said Risinger as quoted by Reuters.

Pfizer has also licensed its inflammatory autoimmune disease drug brepocitinib to Roivant in exchange for a 25 percent stake in another jointly held company called Priovant.

(With inputs from Reuters)

ALSO READ | Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for breast cancer tablets

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 02-12-2022 at 02:26:46 pm
Photos
7 Photos
Nepal plane crash: Flight with 72 onboard crashes near Pokhara International Airport – Images
7 Photos
Business heads run at Mumbai Marathon, more than 50,000 people participate in event – See pictures here
9 Photos
Himachal snowfall: Tourist footfall increases in snow-clad Shimla, other regions of hill state – Pictures inside